Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
about
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseA systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney diseasePolycystic liver diseases: advanced insights into the molecular mechanismsExperimental therapies and ongoing clinical trials to slow down progression of ADPKDTolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseRare cystic liver lesions: a diagnostic and managing challenge.Current management of noninfectious hepatic cystic lesions: A review of the literatureEvaluation of hepatic cystic lesionsSafety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes.Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.Isolated polycystic liver disease.The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regressionReducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.Polycystic liver diseases.Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.Treatment strategies and clinical trial design in ADPKDRationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney diseaseImaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.ADPKD: Prototype of Cardiorenal Syndrome Type 4Liver involvement in early autosomal-dominant polycystic kidney diseaseTolvaptan plus pasireotide shows enhanced efficacy in a PKD1 modelAspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trialEverolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trialClinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.Medical therapy for polycystic liver disease.Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney diseaseUrsodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.Volume regression of native polycystic kidneys after renal transplantation.Complications arising in simple and polycystic liver cysts.Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.Laparoscopic surgery and polycystic liver disease: Clinicopathological features and new trends in management.Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.Heterotrimeric G protein signaling in polycystic kidney disease
P2860
Q24186484-DE9AAFE0-6D8F-49A9-8F1D-65561238DCA5Q26798115-D9EF22C2-6B86-47C3-817B-9D149EB6EA51Q27001174-FDDEBF32-3B5D-4CDC-AF01-F5B96F754841Q27001230-F1583793-2FAF-45CD-91A1-695F2D13B4C9Q29037884-B8E3A7A1-0580-4883-8EDF-8C8F91660128Q30446819-5363D548-2551-46E9-9B41-2DA42C22C41BQ30448914-D4A8E25E-F9E7-4756-ABFA-DCDC34E182F4Q30453209-0BD4CB17-A401-42EF-8279-A4EED9E0554CQ30651564-14278EAA-25D1-4063-A79A-07A4459C4E4CQ33437890-042477D3-B599-4763-AF46-267F29371444Q33702355-F83B2C6D-F416-4F5C-BCE6-8B4705896A93Q33723830-A4BCC1D6-A19E-493A-BB59-4EF9E023FD15Q33730091-891943E2-034D-4F7C-8E93-73931819D15CQ33827422-5F41DD47-B9D1-4AA2-B833-48CF8529574DQ33873050-8E8E028A-8052-4132-90EF-11ADAC0C0E58Q33949172-280D4E2E-0133-4D53-A9E6-BBE198EFC6D6Q33979298-48D5612D-8C29-4619-9AC7-7432D9FBFBB5Q34024396-6DDF73B8-7359-4728-999A-E744012FC861Q34220059-B079A935-90E0-4A32-971B-D0AD043AE03FQ34423262-F4AD47E3-DDEE-4E88-90A4-03AAABA72336Q34467747-DF363832-9D54-4058-917B-AF74E8DFD43DQ34475590-269621BF-9049-45BD-BF60-C4F545F78F36Q34713846-3279F9C1-9284-48B1-BED3-F00EA732ECABQ34787786-563C7196-D3C0-4531-A1CF-0884D18D873DQ35163905-A63B20FA-F93C-4869-B35A-79CF11230C73Q35619287-F748D336-C6DC-40FC-B506-40C58AF73BE1Q35862300-FEE6DAF1-B33F-43F8-83ED-E62E74C2485EQ35873958-D3DA9BCC-CC22-42CE-A505-9D8E466386B9Q35917458-A392CDF9-9EAA-4C3A-8F63-72F5D51AF85FQ36075389-C5F431DA-91E9-4224-A13F-8E6FF2257A3CQ36208594-B4639B9D-F4C6-447D-BEAD-402616B4A951Q36312676-EFE536C6-5EE5-4525-8649-BDB060AE963DQ36422436-849F5A6D-C4FB-4D9A-8D9F-ACF85C5131ECQ36435509-140BBFE0-8130-4A5B-B617-1178ECFA2EEDQ36561607-F4C138FC-9CAD-44AD-8A16-23E99866EB7FQ36926935-D1285A9D-4372-4E95-A49A-604E366279D6Q37028071-AF801F18-8823-4BB5-99CC-3F3A064493B9Q37029861-17A6E299-D7EF-406E-B406-2AC590FBE679Q37055473-7B8B3396-2C77-4FA1-9F81-515D3FC3E49DQ37139683-405FB9C9-06FC-4B0C-BD88-7D763E5F9F0F
P2860
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@en
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@nl
type
label
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@en
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@nl
prefLabel
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@en
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@nl
P2093
P1433
P1476
Lanreotide reduces the volume ...... ind, placebo-controlled trial.
@en
P2093
Aswin L Hoffmann
Frederik Nevens
Helena M Dekker
Joost P H Drenth
Loes van Keimpema
Martijn G H van Oijen
Ragna Vanslembrouck
Robert A de Man
P304
1661-8.e1-2
P356
10.1053/J.GASTRO.2009.07.052
P407
P577
2009-07-29T00:00:00Z